Clinical trial
Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38…
NCT00205478 · Vertex Pharmaceuticals Incorporated, Industry · Completed
Key facts
| NCT number | NCT00205478 |
|---|---|
| Title | Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 |
| Official title | A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | VX-702 |
| Enrollment | 300 |
| Start date | Jun 1, 2005 |
| Completion | Feb 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Dec 7, 2007 |
| Countries | Bulgaria, Croatia, Czechia, Poland, Russia, Serbia and Montenegro, Slovakia, Slovenia, Ukraine |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: